Therefore, drugs with a potent antihyperglycemic effect, independent of the glomerular filtration rate, with a low risk of hypoglycemia, that reduce weight in overweight/obese patients and that provide cardiovascular and renal protection, such as GLP-1 receptor agonists, are needed
Lal N, Kumar J, Erdahl WE, Pfeiffer DR, Gadd ME, Graff G, Yanni JM (2009) Differential effects of non-steroidal anti-inflammatory drugs on mitochondrial dysfunction during oxidative stress
Your knee
Strother says that when it comes to weight loss, most patients see steady progress over time and typically reach a plateau around 72 weeks (a little over a year)
Risks associated with mass-produced compounded GLP-1s Although the FDA has declared that the supply shortage is resolved, some companies continue to mass produce compounded versions of GLP-1s, claiming that the drugs are personalized for patient needs by altering the method of delivery (e.g., gummy, injection, spray) or adding unnecessary and unproven ingredients like B12 and glycine
These measures are straightforward to calculate and have been successfully used to develop predictive disease biomarkers previously 25